What is Chardan Capital's Estimate for ABUS FY2025 Earnings?

Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Chardan Capital boosted their FY2025 EPS estimates for shares of Arbutus Biopharma in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.30) per share for the year, up from their previous estimate of ($0.38). Chardan Capital has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma's current full-year earnings is ($0.39) per share.

Several other analysts also recently issued reports on the stock. StockNews.com raised shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $5.50.

Arbutus Biopharma Price Performance

ABUS traded down $0.04 on Thursday, hitting $3.47. The company had a trading volume of 359,470 shares, compared to its average volume of 861,837. The stock has a market cap of $656.59 million, a price-to-earnings ratio of -8.06 and a beta of 1.93. The company's fifty day moving average price is $3.34 and its 200 day moving average price is $3.55. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.72.

Remove Ads

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp raised its holdings in Arbutus Biopharma by 50.2% in the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock valued at $16,967,000 after acquiring an additional 1,472,652 shares in the last quarter. Rangeley Capital LLC acquired a new stake in Arbutus Biopharma in the 4th quarter valued at about $4,771,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Arbutus Biopharma by 218.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock valued at $4,667,000 after acquiring an additional 831,663 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Arbutus Biopharma by 900.4% in the 4th quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock valued at $2,931,000 after purchasing an additional 806,672 shares during the period. Finally, Whitefort Capital Management LP boosted its position in shares of Arbutus Biopharma by 2.9% in the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company's stock worth $43,301,000 after purchasing an additional 373,949 shares during the last quarter. Institutional investors own 43.79% of the company's stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.